Table 1.
Characteristics of 590 female survey respondents who self-identified themselves as females with a diagnosis of either common variable immune deficiency or hypogammaglobulinemia
| Characteristics | Details |
|---|---|
| All female | |
| Self-reported diagnosis, N = 590 (%) | |
| -CVID | 490 (83) |
| -Hypogammaglobulinemia | 100 (17) |
| Age distribution of respondents (years) |
Average: 49 Range: 18 to 81 Median: 50 |
| Geographic distribution | All 50 US States, District of Columbia and Puerto Rico |
| Duration of condition from diagnosis, in years, N = 582 |
Average: 10.4 Range: Less than 1 to 57 Median: 7.1 |
| Duration of IgG replacement therapy, in years, N = 545 |
Average: 9 Range: Less than 1 to 47 Median: 7 years |
| Modality of IgG replacement therapy ever received, N = 590 (%) | |
| -Intravenous route | 485 (82) |
| -Subcutaneous route | 284 (48) |
| -Intramuscular route | 38 (6) |
| -Intravenous and subcutaneous | 226 (38) |
| -Subcutaneous and intramuscular | 23 (4) |
| -Intravenous and intramuscular | 35 (6) |
| -Intravenous, subcutaneous and intramuscular | 22 (4) |
| -Never treated with IgG | 19 (3) |
| Frequency of IgG replacement therapy | |
| -Intravenous route, N = 267, (%) | |
| • Every week | 11 (4) |
| • Every 2 weeks | 20 (7) |
| • Every 3 weeks | 61 (23) |
| • Every 4 weeks | 161 (61) |
| • Every 5 weeks | 1 (<1) |
| • Every 6 weeks | 12 (4) |
| -Subcutaneous route, N = 232 (%) | |
| • Daily | 1 (<1) |
| • Twice a week | 2 (9) |
| • Three times a week | 1 (4) |
| • Weekly | 198 (85) |
| • Every 2 weeks | 3 (1) |
| Dose of IgG received as replacement therapy | |
| -Intravenous route (N = 240) | Average in grams |
| • Every week | 34 |
| • Every 2 weeks | 32 |
| • Every 3 weeks | 40 |
| • Every 4 weeks | 36 |
| • Every 5 weeks | 25 |
| • Every 6 weeks | 28 |
| -Subcutaneous route (N = 218) | Average in milliliters |
| • Daily | 10 |
| • Twice a week | 40 |
| • Three times a week | 38 |
| • Weekly | 54 |
| • Every 2 weeks | 39 |